10 assets in Von Hippel-Lindau Disease

Therapeutic assets addressing Von Hippel-Lindau Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Belzutifan Von Hippel-Lindau Disease	Merck Sharp & Dohme LLC	P3	BB (64)
Cabozantinib Von Hippel-Lindau Disease	Merck Sharp & Dohme LLC	P3	B (60)
Everolimus Von Hippel-Lindau Disease	Merck Sharp & Dohme LLC	P3	B (60)
Lenvatinib Von Hippel-Lindau Disease	Merck Sharp & Dohme LLC	P3	B (60)
Nivolumab Von Hippel-Lindau Disease	Merck Sharp & Dohme LLC	P3	B (60)
Palbociclib Von Hippel-Lindau Disease	Merck Sharp & Dohme LLC	P3	B (60)
Rvp-001 Von Hippel-Lindau Disease	Reveal Pharmaceuticals Inc.	P2	B (57)
Oxodotreotide Von Hippel-Lindau Disease	National Cancer Institute (NCI)	P2	CCC (53)
Bpi-452080 Von Hippel-Lindau Disease	Betta Pharmaceuticals Co., Ltd.	P1	CC (43)